

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

In the Claims:

1. (Currently Amended) A method of enhancing cytotoxicity elicited by a therapeutic antibody in a subject, which method comprises disrupting activation of SHIP by Fc-gamma-receptor IIB (FcγRIIB) caused by binding of the antibody to FcγRIIB, wherein the disrupting is accomplished by modifying the Fc region of the antibody to reduce its affinity for FcγRIIB, thereby inhibiting binding of the antibody to FcγRIIB in the subject while retaining or enhancing binding to activating Fc receptors, and wherein the Fc region of the antibody is at least 80% homologous with a native Fc region.

2-9. (Canceled)

10. (Original) The method according to claim 1, wherein the antibody is an anti-tumor antibody.

11. (Original) The method according to claim 10, wherein the antibody is specific for a tumor cell growth receptor.

12. (Original) The method according to claim 11, wherein the antibody is specific for a HER2/neu growth factor receptor.

13. (Original) The method according to claim 1, wherein the antibody is specific for a CD20 B cell antigen.

14. (Canceled)

15. (Original) The method according to claim 14, wherein the subject expresses human Fc receptors.

16-22. (Canceled)

23. (New) The method according to claim 1, wherein the wherein the Fc region of the antibody is at least 90% homologous with a native Fc region.

24. (New) The method according to claim 1, wherein the wherein the Fc region of the antibody is at least 95% homologous with a native Fc region.

25. (New) The method according to claim 1, wherein the wherein the Fc region of the antibody comprises 1 amino acid substitution compared to the native Fc region.

26. (New) The method according to claim 1, wherein the wherein the Fc region of the antibody comprises 1-5 amino acid substitutions compared to the native Fc region.

27. (New) The method according to claim 25, wherein the wherein the Fc region of the antibody consists of 1 amino acid substitution compared to the native Fc region.

28. (New) The method according to claim 25, wherein the antibody is specific for a HER2/neu growth factor receptor.

29. (New) The method according to claim 25, wherein the antibody is specific for a CD20 B cell antigen.

30. (New) The method according to claim 1, wherein the wherein the Fc region of the antibody comprises 1 amino acid addition compared to the native Fc region.

31. (New) The method according to claim 1, wherein the wherein the Fc region of the antibody comprises 1-5 amino acid additions compared to the native Fc region.

32. (New) The method according to claim 30, wherein the wherein the Fc region of the antibody consists of 1 amino acid addition compared to the native Fc region.

33. (New) The method according to claim 30, wherein the antibody is specific for a HER2/neu growth factor receptor.

34. (New) The method according to claim 30, wherein the antibody is specific for a CD20 B cell antigen.
35. (New) The method according to claim 1, wherein the wherein the Fc region of the antibody comprises at least 1 amino acid deletion compared to the native Fc region.
36. (New) The method according to claim 35, wherein the wherein the Fc region of the antibody consists of 1 amino acid deletion compared to the native Fc region.
37. (New) The method according to claim 35, wherein the antibody is specific for a HER2/neu growth factor receptor.
38. (New) The method according to claim 35, wherein the antibody is specific for a CD20 B cell antigen.